for assessment. Criteria for inclusion in the study included the following: requirement for hospitalization, age of~18 years, and presence of diabetes mellitus and limb-threatening infection involving the lower extremity (limb-threatening infection was defined by at least the presence ofcellulitis, with or without ulceration or purulent discharge). Exclusion criteria included the following: known hypersensitivity to fJlactam antibiotics; requirement for other concomitant antibiotic treatment; serum creatinine level of~3.5 mg/dl.; pregnancy; illness so severe that the patient was likely to die within 48 hours; severe underlying disease that might interfere with evaluation of the therapeutic response; immune depression by virtue of underlying disease, prior organ transplantation, or immunosuppressive drug therapy; and current involvement in a clinical study of an investigational drug. Patients who had recently received antibiotic therapy but had failed to demonstrate clinical improvement and whose cultures revealed one or more pathogens were eligible, unless the antimicrobial spectrum ofthe preceding therapy was comparable to that of the study agents.
At enrollment, informed written consent and basic demographic data were obtained. Prior to the initiation of therapy, all patients underwent a physical examination; a blood culture was performed; aerobic and anaerobic cultures of the deep wound (if present) and tissue (if debridement was indicated) were performed; and the hemoglobin level, leukocyte and platelet counts, clotting time, hepatic and renal function, blood glucose concentration, and urine were assessed. When the clinical history suggested that the infection may have been acquired nosocomially (e.g., from an earlier hospital admission), this was noted. The clinical assessment of signs and symptoms was made in a blind fashion by the study physicians (M. L. G. and A. W. K.) on a daily basis for the initial 6 days and regularly thereafter until therapy was completed. The assessment included documentation ofthe diameter and depth of any ulceration and the extent of cellulitis, lymphangitis, tissue necrosis, and purulent discharge. Daily insulin dosages were recorded during treatment. All instances of sharp debridement, amputation, and vascular reconstruction were recorded.
Patients were assigned by the pharmacy to receive either I/C or A/S on the basis of a computer-generated randomization code. The usual dosage of A/S was 2 g of ampicillin/ 1 g of suibactam (3 g total) iv every 6 hours, and that of I/C was 500 mg iv every 6 hours. The creatinine clearance was calculated with use of the equation of Cockcroft and Gault [7] . For patients with impaired renal function, the following dosage adjustments were made by a third party who did not participate in the clinical care or evaluation of the patients. For A/S, when the creatinine clearance was~30 ml.Zmin, the full dosage was used; when it was 15-29 mL/min, the dosage was l. 5-3 g every 12 hours; and when it was < 15 mL/min, the patient was excluded from the study. For I/C, when the creatinine clearance was> 30 mL/min, the full dosage was given; if it was 21-30 mL/min, the dosage was 500 mg every 8 hours; and if it was~20 mL/min, the patient was excluded from the study. Administration of study medication was commenced within 12 hours after the time of initial wound cultures.
Aerobic and anaerobic cultures of the deep wound (or debrided tissue) were performed at least four times: on days 0, 3, and 5 and on the final day of parenteral antibiotic treatment. Before specimens were obtained for cultures, the skin surrounding infected wounds was cleansed with sterile saline. Subsequently, overlying eschar or devitalized skin was sharply debrided, where necessary, and specimens for culture were obtained by swab from the base of the wound. If initial sharp debridement was necessary, tissue from the wound base was submitted for culture. When present, loculated pus was aspirated and submitted in a capped syringe for culture. Swabs from the skin surface were not accepted. Swabs for anaerobic culture were transported in an Anaerobic Culturette Collection System (Becton Dickinson, Cockeysville, MD). Specimens were taken promptly to the microbiology laboratory for processing.
Specimens were cultured in a standard manner for isolation and identification ofaerobes (Combo Plus Type 3 Gram Negative Microscan Panels; Baxter Healthcare Corporation, West Sacramento, CA) and anaerobes (Rapid II Ana Systems; Innovative Diagnostic Systems, Norcross, GA). Cultures for anaerobes were planted in a standard hood on prereduced anaerobic brain-heart infusion agar supplemented with yeast extract, vitamin K, and 5% sheep blood; on prereduced kanamycin-vancomycin anaerobic Columbia agar supplemented with hemin, vitamin K, and laked 5% sheep blood (both agars were made in-house); and in thioglycollate broth enriched with hemin and vitamin K (Becton Dickinson). Plates for anaerobic culture were incubated in an oxoid gasgenerating kit (anaerobic system BR38; Unipath Ltd., Basingstoke, Hampshire, England). Aerobic cultures were planted on trypticase soy agar supplemented with 5% sheep blood, on MacConkey's agar, and in enriched thioglycollate broth (all Becton Dickinson). Anaerobic plates and thioglycollate broth preparations were incubated and observed for 6 days before considered negative. Blood was cultured by inoculation of 5 mL into a Bactec 6A aerobic and Bactec 7N anaerobic blood culture bottle (Becton Dickinson); these were processed with use of the NR -660 Bactec analyzer. Tissue and bone specimens were ground prior to being cultured.
All pathogens were tested for susceptibility to A/S and IjC by broth dilution or disk-diffusion methods, in accordance with guidelines M2-A3, M7-A, MII-T2, and MII-A of the National Committee for Clinical Laboratory Standards . fJ-Lactamase production was assessed by means of a nitrocefin disk. All isolates cultured from blood, wound, deep tissue, and bone were considered pathogens except for Corynebacterium species, Candida species, and coagulase-negative staphylococci; these were regarded as contaminants un-less they were recovered as sole isolates from deep tissue or bone.
The presence of osteomyelitis was recognized on the basis of appropriate histopathologic, radiological, or clinical criteria. Histopathologic examination of bone was performed by a pathologist with expertise in bone pathology. Acute osteomyelitis was defined by the presence within the bone ofacute inflammation, often accompanied by focal necrosis of bone and intertrabecular soft tissue. Low-grade chronic osteomyelitis was characterized by plasma cell and lymphocytic infiltration, increased vascularity, and fibrosis, often with only focal osteoblastic and osteoclastic activity. Osteomyelitis was demonstrated on plain radiographs by evidence ofthe lysis of cortical bone and loss of the trabecular bone pattern. Although rarely used, a triple-phase technetium-99m bone scan in which there was a differential increase in technetium99m uptake of bone in the clinically infected region was accepted as being suggestive of underlying osteomyelitis. Scans using indium Ill-labelled leukocytes or gallium, computed tomography, and magnetic resonance imaging were not performed in this study. Osteomyelitis could be diagnosed clinically by the presence of purulent, friable bone. Histopathologic findings, however, were the final arbiter for the presence or absence of osteomyelitis. When histologic data were not available, radiological or clinical evidence of osteomyelitis was accepted. Osteomyelitis was considered to be present if detected either at study enrollment or at the index site within 6 months after study completion.
Because pathogen identification and antimicrobial susceptibility testing is frequently not complete for 5 days in cases of polymicrobial infection, the initial 5 days or 120 hours of study therapy were considered to be the period of empirical therapy. A clinical and microbiological assessment was made at the end of empirical therapy. A final assessment of treatment outcome was made at the end of iv antimicrobial therapy. The following clinical endpoints were used: cure (resolution of soft-tissue infection), improvement (alleviation of~2 presenting signs or symptoms of infection), failure (inadequate improvement, necessitating a change in antibiotic therapy), and indeterminate (clinical assessment not possible, e.g., because of amputation of the entire site of infection). Microbiological endpoints were eradication (clearance of principal pathogenes) from the wound, including tissue or bone if cultured), partial eradication (clearance of some but not all pathogens), persistence (persistence of principal pathogens), and superinfection (elimination of the principal pathogens but emergence of a new pathogen during treatment).
With the exception of the antibiotic use mandated by the study, patients' therapy was routine and consisted of bed rest, surgical drainage and debridement of infected ulcers and necrotic tissue, vigorous control of diabetes mellitus, and use of sterile wound dressings (gauze soaked with normal saline or one-quarter-strength povidone-iodine). When appropriate, arterial circulation of the lower limb was evaluated by noninvasive and arteriographic techniques. Surgery to improve the arterial circulation or amputation of unsalvageable tissues was performed at the discretion of the attending surgeon.
When patients adequately responded to empirical therapy and all isolated pathogens were susceptible to both study antibiotics, blind treatment with the initially assigned regimen was continued until parenteral antibiotics were no longer necessary. Similarly, for patients who had an adequate response to empirical therapy but whose wound culture yielded a potential pathogen that was resistant to one of the study antibiotics, blind parenteral antibiotic treatment was completed with the assigned study antimicrobial. When a patient's clinical response was unsatisfactory and a potential pathogen that was resistant to either study agent was recovered, blinding was maintained but antibiotic therapy was revised by the attending physicians. When patients were determined to have an unsatisfactory clinical response to empirical therapy but no pathogen resistant to either study antibiotic was isolated, blinding was maintained but antibiotic therapy could be revised at the discretion of the attending physicians. Revision of the treatment regimen could entail replacing the study drug with another antibiotic or adding another antimicrobial to the study regimen. All patients continued to be evaluated regularly for the adequacy of clinical and microbiological responses, regardless ofwhether the antibiotic regimen was altered. After completion of the study therapy, a brief course of oral antibiotics could be administered to patients at the discretion of the attending surgeon.
Adverse experiences were graded according to the following criteria: signiJicant-a severe reaction necessitating withdrawal of the study agent or specific treatment; moderatej possible-a reaction that did not necessitate withdrawal of the study agent or specific treatment; and mild/unlikely-an event uncertainly associated with the study drug. If an urticarial or morbilliform rash developed, the study drug was withdrawn.
Statistical analysis of the frequency of categorical results was performed with use of the x infections were each treated with I/C, and each of the third patient's infections was treated with a different study regimen. Another of the five patients had two episodes of infection at the same site (12 months apart), with complete healing between episodes; one infection was treated with A/S and one with I/C. In the fifth patient who was enrolled twice, the second episode was considered a recurrence; the infection occurred at the same site .5 weeks after the initial episode. Although all signs of soft-tissue infection had resolved and all pathogens had been eradicated, the initial ulcer had not healed. Because all initial pathogens had been susceptible to both study regimens, the patient was reenrolled in the study. Both episodes were randomized to treatment with Ijc. Thus, 48 infections occurring in 47 patients were treated with A/S and 48 infections occurring in 46 patients were treated with IjC. The mean age of patients receiving A/S and the duration of their diabetes were 59 years and 20 years, respectively; these features were similar for patients receiving I/C (61 years and 19 years, respectively). Of those treated with A/S and I/C, 30 and 37, respectively, were men. Patient characteristics and features of infection are shown in table 1. The vast majority of patients had relatively acute infection or exacerbated chronic infection with prominent local signs of aggressive infection. Patients in the treatment groups were similar in regard to severity ofdiabetes and presence of peripheral vascular disease, sensory neuropathy, and renal impairment. The sites and severity of infection, including the frequency of osteomyelitis, were similar for both treatment groups.
The results ofwound cultures are shown in tables 2 and 3. The number of patients in each treatment group from whom pathogens were isolated that were resistant or potentially resistant to either A/S or IjC was similar. Not surprisingly (given the antimicrobial spectrum of the agents being studied), potential pathogens that were resistant or potentially resistant to the assigned study drug were found more frequently in patients treated with A/S than in those receiving I/C (16 vs. 4 ; P = .006). However, this difference was not reflected in the outcomes of cases treated with IjC versus A/S. The infections of seven patients were nosocomial and related to prior hospitalizations. Bone cultures yielded pathogens for 11 of 12 patients treated with A/S and 7 of 8 patients treated with I/C (table 1).
The total numbers of antibiotic doses and days of treatment given to patients in the two groups were similar (table 4). In both the A/S and I/C treatment groups, patients in 45 episodes completed the 20-dose regimen of empirical treatment. In two of the 48 episodes treated with A/S, early clinical failure necessitated the addition of another antibiotic to the regimen. In a third episode, an A/S-treated patient was discharged after 4 days of therapy (10 doses) for personal reasons but was clinically cured at the time of discharge. In the I/C treatment group, patients in two episodes inadvertantly received only 19 doses of study drug; both were clinically cured at this point (day 5). In a further episode, a patient who complained of marked nausea was given only 13 doses during the initial 5 days; nevertheless, this resulted in clinical cure and microbiological eradication by the day-5 assessment.
Significant study violations, occurring after completion of the initial 5-day period of empirical treatment, were defined as~2 missed doses of study drug or the non sanctioned administration ofa nonstudy antibiotic. The frequency of these violations was similar for both treatment groups (table 4). In spite ofthe physicians' orders, three doses ofthe study antibiotic were not administered to one patient in the A/S group and three patients in the I/C group. In the A/S group one patient each received a single dose ofcefoxitin or metronidazole, and in the I/C group one patient received a single dose of A/S. Topical antibiotics were briefly applied to the wounds of two patients in the I/C group. These protocol violations occurred as a result ofphysicians' errors in medication orders; they were not prompted by a clinical indication for a change in treatment, and they resulted in no apparent benefit. Renal dysfunction, induced by administration of radiocontrast dye, necessitated adjustment of the antibiotic dosage in two A/S-treated and three I/C-treated episodes.
After 5 days of empirical treatment and at the completion ofparenteral antibiotic therapy, the clinical and microbiological outcomes of treatment were similar for the two study groups (table 5) . Upon completion of definitive parenteral therapy, cure was achieved in 81% of episodes treated with A/S and 85% of those treated with I/C (difference in cure rates, 4%; 95%confidence interval, -II %to 19%). Additionally, the clinical and microbiological responses to the two regimens were similar when the analysis was stratified to compare only episodes of infection limited to soft tissues. In the eight episodes in which treatment with A/S failed, the study agent was replaced with an alternative antibiotic, which was I/C in one episode (blinding was maintained). In 36 of the 39 infections cured with A/S, the only parenteral antibiotic administered was A/S. After a clinical cure of softtissue infection was achieved and all pathogens were eradicated, patients in three of these A/S-treated episodes received nonstudy antimicrobials parenterally because of the occurrence of an adverse event or for convenience in home therapy (table 4). In the six episodes of infection in which treatment with I/C failed, the study regimen was replaced with an alternative antibiotic (blinding was maintained); two of these patients were treated with I/C and responded. In 38 of 41 episodes in which patients were cured with I/C, the only parenteral antimicrobial agent received was I/C. After soft-tissue infection was cured and all pathogens were eradicated, patients in three ofthese I/C-treated episodes received nonstudy parenteral antibiotics because of the occurrence of adverse events (table 4) .
Surgical drainage of loculated pus and debridement of necrotic tissue, including bone when osteomyelitis was present, t Denominator (on which percentage is based) indicates no. of episodes for which the indicated assessment was made. § In three further cases. bone was histologically examined during the follow-up period, and in two of the three there was evidence of osteomyelitis.
II In one further case, there was histologic evidence of periostitis without osteomyelitis. # Diagnosis of osteomyelitis was based on histologic appearance of bone, results of bone culture, or clinical presence of purulent. nonviable bone. ** One patient was omitted from this analysis. Although there was no clinical evidence of osteomyelitis, definitive classification was not possible because bone was not examined pathologically at the time of foot amputation.
was performed in the majority of patients (table 4). Amputations, which were performed on 33 (69%) of the AjS-treated patients and 28 (58%) of those treated with IjC (P = .25), were done primarily as part of our standard aggressive protocol for ablative debridement ofosteomyelitic bone. Ofthe 61 amputations, 57 were limited to the infected digits and metatarsal heads and thus were considered foot-sparing procedures (i.e., functional weight-bearing was preserved). Four patients (of whom three received AjS and one was treated with I/C) had below-the-knee amputations. These were performed because it was noted at the time of admission either that osteomyelitis had undermined the structural integrity of the foot or that an unreconstructable vascular supply had rendered the foot unsalvageable. The clinical conditions of two of these patients were classified as indeterminate at cessation of study therapy because all assessable soft-tissue infection had been removed; for two other patients, substitution of a non protocol antibiotic was necessitated before below-the-knee amputation, so their study treatments were therefore classified as failures.
Surgery rarely resulted in the total resection of all infected tissue. Amputation was undertaken before the day-5 assessment in 16 of the 33 A/S-treated patients and six of the 28 I/C-treated patients for whom the procedure was required (P > .05); however, the rates of clinical improvement due to study medication prior to any amputation were similar for both treatment groups (12 of 33 vs. 17 of28; P = .10). Similarly, amputation may have impacted upon the speed of pathogen eradication, but there was little difference between the two treatment groups in this respect. Among patients who had amputations, pathogen eradication was achieved by the day-5 assessment for 11 ofthe 33 A/S-treated and nine of the 28 I/C-treated patients (P = .86). At completion oftherapy, pathogen eradication had been achieved for 20 A/Streated and 21 I/C-treated patients; 19 patients in each group underwent their initial amputation before this assessment.
Vascular reconstruction to allow healing of ulcers or surgical wounds was performed in 22 episodes (seven treated with A/S and 15 with I/C). Of the 59 infections associated with osteomyelitis, 56 were treated with a combination of antibiotic therapy and resection of infected bone and soft tissue (either aggressive debridement or amputation). Three patients with osteomyelitis did not immediately undergo aggressive debridement; in each patient, osteomyelitis became apparent at the time of recurrence after successful treatment for soft-tissue infection. Undetected osteomyelitis was presumed to have been present during the initial treatment. At the time of recurrence, each patient had ulcerated soft-tissue infection contiguous to the osteomyelitis, and each was treated with antibiotics and aggressive surgery.
The frequency of treatment failures was similar for both treatment groups (tables 5 and 6). The isolation from wounds of pathogens that were resistant or potentially resistant (by virtue of inducible ,B-lactamase) to the study antibi- otic administered was significantly associated with clinical treatment failure noted at the end oftherapy. The pathogens grown in 19 of the wound cultures performed on day 0 were resistant or potentially resistant to the assigned antibiotic. In another episode, a patient had infection with a coagulase-negative staphylococcus that was not tested for antibiotic susceptibility but was considered resistant clinically. This coagulase-negative staphylococcus persisted in wound and bone cultures and was associated with clinical antibiotic failure. Of these 20 episodes, therapy failed for 10 (seven treated with A/S and three with I/C); in comparison, three failures occurred among 70 patients whose wounds yielded only organisms documented to be susceptible to the assigned study antimicrobial (P < .001). Among the patients with initially susceptible pathogens, a further clinical failure occurred in an IjC treated patient whose wound became super-infected with a gram-negative bacillus that was resistant to both study agents. Thus, of 16 A/S-treated episodes in patients whose wounds yielded an A/S-resistant pathogen, in only seven (44%) did treatment fail; by contrast, treatment failure was noted in four of five I/C-treated episodes in patients whose wounds yielded an I/C-resistant isolate. Furthermore, treatment failure, regardless of the antibiotic administered, was strongly associated with infection that was nosocomially acquired. For five of seven nosocomial infections (vs. nine of 89 nonnosocomial infections), treatment failed (P < .001).
Underlying osteomyelitis was associated with 11 of the 14 failures (six infections treated with A/S and five with I/C; table 6). However, among all patients, osteomyelitis was not associated with failure to eliminate soft-tissue infection; at the end of therapy, treatment failure was noted in 11 (19%) of the 59 infections in patients with osteomyelitis and three (8%) of the 37 infections in patients without osteomyelitis (P = .26). It is likely that the successful treatment of soft-tissue infection in patients with osteomyelitis was aided by our use ofaggressive ablative debridement ofinfected necrotic bone, including the performance offoot-sparing amputations. Nevertheless, the extent of surgical intervention in patients with osteomyelitis could not be correlated with the success or failure of antibiotic therapy in eradicating soft-tissue infection.
Data regarding the long-term follow-up of patients who were assessed as clinically cured at study completion are noted in table 7. The average duration of follow-up was r-1 year for both treatment groups. Recurrence of infection at the original site was noted in nine of 39 assessable patients treated with A/S and eight of 41 assessable patients who re- SD], 12.5 ± 5.8 (A/S) and 16.5 ± 8.3 (I/C); P = .12). Eradication of bone infection with regimens of a duration that targeted soft tissue likely reflects the benefit of aggressive ablative surgical debridement. Notably, all three patients with initially unrecognized osteomyelitis who were not treated surgically had recurrence of infection at the initial site. The number of patients whose infection relapsed within 13 weeks after study completion was similar in the two groups. The initial pathogen was reisolated during this early relapse from five of the 10 patients. Freedom from recurrence of infection at the original site after long-term followup was documented in 27 (56%) of the 48 episodes treated with A/S vs. 33 (69%) of the 48 episodes treated with I/C (P = .29). Thus, overall, 60 (63%) of the 96 infections treated during this study responded to the initial study antibiotic and did not recur during an average follow-up of ,...., 1 year.
The total incidence of adverse reactions was similar in both treatment groups (table 8) . Antibiotic-associated diarrhea was the most common adverse event among patients in each group. Diarrhea related to Clostridium difJicile occurred more frequently in patients treated with I/C than in those treated with A/S, but this difference was not significant (P = .14). Nausea, however, was significantly more common in patients treated with I/C (8 of 48 episodes) than in those treated with AjS (l of 48 episodes) (P = .04).
Discussion
Lower-limb infections in diabetic patients are frequently caused by a mixture of aerobic and anaerobic pathogens [3] [4] [5] [6] [12] [13] [14] that often necessitate the use of a combination of antibiotics plus surgical debridement for cure [2, 6, 15] . Because of the likely presence of diabetes-associated renal impairment, it is desirable to avoid administering potentially nephrotoxic agents such as aminoglycosides to these patients. Antimicrobial agents such as {j-lactaml{j-lactamaseinhibitor combinations and the carbapenems (e.g., imipenem) are attractive treatment options because of their broad spectrum of activity and relative lack of renal toxicity.
I/C has antimicrobial activity against an extremely broad spectrum of organisms, including the majority of strains of Pseudomonas aeruginosa and almost all Enterobacteriaceae and anaerobes [16] . The {j-lactaml{j-lactamase-inhibitor combination of A/S has activity similar to but less broad than that of I/C; it is unreliable against Enterobacteriaceae that are capable of producing inducible Class 1 {j-Iactamases (e.g., Serratia, Acinetobacter, Citrobacter, Enterobacter, Morganella, and certain Proteus species) [17, 18] and inactive against strains of P. aeruginosa [19] . Nevertheless, whether extremely broad-spectrum antibiotics such as I/C demonstrate clinical superiority over agents such as A/S has remained uncertain. This double-blind randomized trial of * Empirical treatment was incomplete for two patients because of drug failure (due to Pseudomonas aeruginosa and Xanthomonas maltophilia. respectively) and for one patient because of personal reasons. t Empirical treatment was incomplete for two patients because of an error and for one patient because of an adverse reaction (severe nausea).
t >2 doses of study drug were missed or a nonstudy antibiotic was administered. lOne patient missed three doses; two patients received one dose ofa nonstudy antibiotic in error (cefoxitin and metronidazole. respectively). treatment for limb-threatening pedal infections in diabetic patients attempted to assess this question by comparing the efficacy of A/S to that of I/C for the initial empirical and definitive parenteral treatment of this condition.
In this study the efficacy of A/S and I/C for the treatment of limb-threatening pedal infection in diabetic patients was similar. Of 48 infections treated with A/S for an average (±SD) of 13 ± 6.5 days, 81% were cured clinically; in 67%, the potential pathogens were eradicated at the end of parenteral therapy. Among the 48 infections treated with I/C for an average (±SD) of 15 ± 8.6 days, 85% were judged to be cured clinically; in 75%, the potential pathogens were eradicated. Furthermore, after follow-up of --I year, 56% of the patients treated with A/S and 69% of those treated with I/C remained free of infection at the site of the original event. Lastly, among patients with osteomyelitis who were treated with aggressive ablative surgical debridement (including foot-sparing amputations) and who were considered cured of soft-tissue infection by relatively short courses ofA/S or I/C, 65% and 73% of patients, respectively, remained free of osteomyelitis during a follow-up of --I year.
Recognizing the limitations in recruiting suitable patients for this study from a single institution, we designed the study protocol so that 40 patients would be randomized into each treatment arm. Assuming an expected clinical response rate of 80% for I/C [20, 21] , the power of this study to show that A/S was no more than 20% less effective than I/C would have been 0.7 [22] . However, we were able to treat 48 infections in each group, thus enhancing the power of the study to detect this difference.
The spectrum of organisms isolated from our patients' wounds is comparable to that reported in recent studies of foot infections in patients with diabetes mellitus [6, [12] [13] [14] 20] . Additionally, the frequency of osteomyelitis (61%) found in association with soft-tissue infection in our patients is similar to that reported by Peterson et al. [13] (64%) and Hughes et al. [14] (49%) in recent trials of antibiotic treatment for foot infections in diabetic patients. In spite of the apparent similarity of the patients treated in various studies, there are major differences between trials in terms of the role of surgery in treating osteomyelitis as well as the definitions of success and failure. These differences limit the reliability of comparisons of outcome of antibiotic therapy for foot infection in diabetics studied in various trials. Nevertheless, it is interesting to note that our experience is comparable to that reported in regard to several recent studies. Hughes et al. [14] reported that use of ceftizoxime (mean daily dose, 8. 1g; mean duration ± SD, 20 ± 12.9 days) and cefoxitin (mean daily dose, 8.1 g; mean duration ± SD, 18.6 ± 14.7 days) resulted in end-of-therapy satisfactory responses in 82% and 68% of patients, respectively. Peterson et al. [13] , using ciprofloxacin at a dosage of 1,500-2,000 mg daily for 3 weeks (for soft-tissue infection) to 3 months (for osteomyelitis), noted a satisfactory response in 37 (79%) of 47 patients. In addition, Calandra et al. [20] , in an open trial ofl/C for skin and soft-tissue infection in the lower extremity of diabetic patients, found that 47% of patients were cured and the conditions of 45% improved.
In our study, the presence of pathogens that were resistant or potentially resistant to the antibiotic being utilized was associated with an increased risk of antibiotic failure. Similarly, for patients whose foot infections were nosocomial (an indication that infection was associated with resistant bacteTable5. Clinical and microbiological outcomesofantibiotictherapy, asassessed on day 5 of empirical therapyand at the conclusion of parenteral therapy. ria), there was an increased likelihood ofantibiotic treatment failure. Nevertheless, our study indicates that treatment with A/S, a moderately broad-spectrum antibiotic, was as effective as treatment with IIC, a notably broader-spectrum antimicrobial. Overall, in spite of the presence of resistant or potentially resistant pathogens in 20 patients at the initiation of therapy, only four of the 96 infections did not improve during the initial 5 days of empirical therapy. Notably, among the 16 patients with A/S-resistant pathogens who were treated with A/S, therapy failed for only seven ultimately and for only three within the initial S-day empirical treatment period. The efficacy of selected antimicrobial agents for treatment of foot infections of which cultured specimens have yielded organisms that are resistant to the antimicrobial agent has been noted by others [6, 23] . Lipsky et al. [23] reported successful treatment of 13 of 14 patients from whom one or more bacterial isolates were recovered that were resistant to the administered antibiotic. These reported successes may reflect the imprecision of cultures of deep-wound specimens in identifying the causative agent of the infection. Alternatively, such unanticipated efficacy may reflect the net impact of adjunctive therapy-particularly surgical debridement and wound care as well as antibiotic use-on the ultimate outcome. Regardless, our data indicate that initiation ofmoderately broad-spectrum antibiotic therapy with A/S, in combination with appropriate surgical therapy, frequently results in clinical cure of limb-threatening pedal infections in patients with diabetes. Furthermore, even in the face of poten- tially A/S-resistant organisms, this therapy provided antimicrobial coverage for a sufficient interval to maintain patient stability until data from initial cultures were available and treatment was revised. These observations demonstrate the No. (%) of patients with adverse reaction appropriateness in cases of serious but non-life-threatening polymicrobial infection of directing empirical therapy against the major anticipated pathogens rather than seeking an all-inclusive regimen.
It is important to note that our study excluded patients with life-threatening (as opposed to limb-threatening) infection. Consequently, we cannot extend our observations on the efficacy of moderate-spectrum antimicrobial therapy in patients with limb-threatening infection to advocate the use of AjS or similar moderate-spectrum antimicrobial agents in the empirical treatment ofdiabetic patients with life-threatening overwhelming sepsis due to an extensive foot infection. In fact, these patients should be treated with maximal therapy, including combinations of antimicrobial agents, determined on the basis of clinical and epidemiological considerations. 
